Autopsy report · NCT00981370

Clinical Importance of Treating Iron Overload in Sickle Cell Disease

“1 consented patient never started on study drug, lost to follow up”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months after it had already started.
• Ran for about 1 year 8 months before it stopped.
• 1 participant enrolled.
• Results were posted on the registry 6 years 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Children's Hospital Los Angeles

Sponsor type

University, hospital or other

Conditions

Anemia, Sickle Cell; Transfusion Hemosiderosis

Interventions

deferasirox

Participants

1

Sites

1

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.